Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline (Q38995175)

8 September 2017

1 reference

title

Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline (English)

1 reference

8 September 2017

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27798208%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Moloko C Cholo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27798208%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Maborwa T Mothiba

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27798208%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Bernard Fourie

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27798208%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

English

0 references

publication date

20 October 2016

1 reference

Journal of Antimicrobial Chemotherapy

8 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27798208%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27798208%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27798208%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

338-353

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27798208%20AND%20SRC:MED&resulttype=core&format=json

Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Management of drug-resistant TB in patients with HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Rising to the challenge: new therapies for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Medical treatment of pulmonary multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Multitarget drug discovery for tuberculosis and other infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Antiinfectives targeting enzymes and the proton motive force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Antimycobacterial activities of riminophenazines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Structure-activity relationships of selected phenazines against Mycobacterium leprae in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Structure-activity relationships of tetramethylpiperidine-substituted phenazines against Mycobacterium leprae in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Inhibition of potassium transport and growth of mycobacteria exposed to clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Antimycobacterial action of B4128, a novel tetramethylpiperidyl-substituted phenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

The riminophenazines, clofazimine and B669, inhibit potassium transport in gram-positive bacteria by a lysophospholipid-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

In vitro investigation of the antimicrobial activities of novel tetramethylpiperidine-substituted phenazines against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine analogs with antileishmanial and antiplasmodial activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine Inhibits the Growth of Babesia and Theileria Parasites In Vitro and In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

An Antifungal Combination Matrix Identifies a Rich Pool of Adjuvant Molecules that Enhance Drug Activity against Diverse Fungal Pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Effectiveness and safety of clofazimine and pentoxifylline in type 2 lepra reaction: a double-blind, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Effects of clofazimine on potassium uptake by a Trk-deletion mutant of Mycobacterium tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Effects of clofazimine on planktonic and biofilm growth of Mycobacterium tuberculosis and Mycobacterium smegmatis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bicephalic amphiphile architecture affects antibacterial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Efficacy of antimicrobial peptoids against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

The effect of binding of chlorpromazine and chloroquine to ion transporting ATPases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Inhibition of the ATPase activity of the catalytic portion of ATP synthases by cationic amphiphiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine and B669 inhibit the proliferative responses and Na+, K(+)-adenosine triphosphatase activity of human lymphocytes by a lysophospholipid-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

State-dependent blocking mechanism of Kv 1.3 channels by the antimycobacterial drug clofazimine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine Induced Suicidal Death of Human Erythrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine Biocrystal Accumulation in Macrophages Upregulates Interleukin 1 Receptor Antagonist Production To Induce a Systemic Anti-Inflammatory State

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

The association between sterilizing activity and drug distribution into tuberculosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine in the treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Acquired resistance of Mycobacterium tuberculosis to bedaquiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Drug-resistance mechanisms and tuberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Evidence for the presence of clofazimine and its distribution in the healthy mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bone distribution study of anti leprotic drug clofazimine in rat bone marrow cells by a sensitive reverse phase liquid chromatography method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Molecular imaging of intracellular drug-membrane aggregate formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

A far-red fluorescent probe for flow cytometry and image-based functional studies of xenobiotic sequestering macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Phagocytosed Clofazimine Biocrystals Can Modulate Innate Immune Signaling by Inhibiting TNFα and Boosting IL-1RA Secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Chemical Analysis of Drug Biocrystals: A Role for Counterion Transport Pathways in Intracellular Drug Disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Anything to Stay Alive: The Challenges of a Campaign for an Experimental Drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bedaquiline for the treatment of drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bedaquiline: a new hope to treat multi-drug resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Microbiology. TB--a new target, a new drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Identification of a novel class of quinoline-oxadiazole hybrids as anti-tuberculosis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Asymmetric Synthesis and Absolute Configuration Assignment of a New Type of Bedaquiline Analogue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Novel antibiotics targeting respiratory ATP synthesis in Gram-positive pathogenic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Rational drug design based synthesis of novel arylquinolines as anti-tuberculosis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Leveraging Advances in Tuberculosis Diagnosis and Treatment to Address Nontuberculous Mycobacterial Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Comparative efficacy and acceptability of five anti-tubercular drugs in treatment of multidrug resistant tuberculosis: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

A protonmotive force drives ATP synthesis in bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

F1F0-ATP synthases of alkaliphilic bacteria: lessons from their adaptations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Diarylquinolines target subunit c of mycobacterial ATP synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bactericidal mode of action of bedaquiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Turning the respiratory flexibility of Mycobacterium tuberculosis against itself

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Riminophenazine compounds: pharmacology and anti-neoplastic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Tuberculosis in 2015: From diagnosis to the detection of multiresistant cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

The chemotherapy of tuberculosis: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Synthetic investigational new drugs for the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

Clinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

A New Series of Phenazines (Rimino-Compounds) With High Antituberculosis Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW426

21 January 2018

Identifiers

DOI

10.1093/JAC/DKW426

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27798208%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference